News Stories

Chicago-area cardiologist assumes role during NLA Scientific Sessions in Las Vegas

ORLANDO (March 10, 2018) – The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally tolerated statin and placebo. 

JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program. The partnership will also include sister publications, Rare Disease Report® and Pharmacy Times®.